Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
Detection of lung cancer at an early stage is necessary for successful therapy and improved survival rates. We performed a bottom-up proteomics analysis using a two-dimensional LC-MS/MS strategy on the conditioned media of four lung cancer cell lines of different histological backgrounds (non-small cell lung cancer: H23 (adenocarcinoma), H520 (squamous cell carcinoma), and H460 (large cell carcinoma); small cell lung cancer: H1688) to identify secreted or membrane-bound proteins that could be useful as novel lung cancer biomarkers. Proteomics analysis of the four conditioned media allowed identification of 1,830 different proteins (965, 871, 726, and 847 from H1688, H23, H460, and H520, respectively). All proteins were assigned a subcellular localization, and 38% were classified as extracellular or membrane-bound. We successfully identified the internal control proteins (also detected by ELISA), kallikrein-related peptidases 14 and 11, and IGFBP2. We also identified known or putative lung cancer tumor markers such as squamous cell carcinoma antigen, carcinoembryonic antigen, chromogranin A, creatine kinase BB, progastrin-releasing peptide, neural cell adhesion molecule, and tumor M2-PK. To select the most promising candidates for validation, we performed tissue specificity assays, functional classifications, literature searches for association to cancer, and a comparison of our proteome with the proteome of lung-related diseases and serum. Five novel lung cancer candidates, ADAM-17, osteoprotegerin, pentraxin 3, follistatin, and tumor necrosis factor receptor superfamily member 1A were preliminarily validated in the serum of patients with lung cancer and healthy controls. Our results demonstrate the utility of this cell culture proteomics approach to identify secreted and shed proteins that are potentially useful as serological markers for lung cancer.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G1X5, Canada.
Chris
C
Planque
Vathany
V
Kulasingam
Chris R
CR
Smith
Karen
K
Reckamp
Lee
L
Goodglick
Eleftherios P
EP
Diamandis
D051722:ADAM Proteins / Q000378:metabolism; D000072198:ADAM17 Protein; D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016466:CHO Cells; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D006224:Cricetinae; D003412:Cricetulus; D017077:Culture Media, Conditioned / Q000032:analysis*; D005110:Extracellular Space / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000378:metabolism*; D013058:Mass Spectrometry; D008565:Membrane Proteins / Q000378:metabolism; D009363:Neoplasm Proteins / Q000737:chemistry / Q000145:classification / Q000378:metabolism; D020543:Proteome / Q000737:chemistry / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results
D014408:Biomarkers, Tumor; D017077:Culture Media, Conditioned; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D020543:Proteome; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human